Page 7 - லூபஸ் ஆராய்ச்சி கூட்டணி பலகை ஆஃப் இயக்குநர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from லூபஸ் ஆராய்ச்சி கூட்டணி பலகை ஆஃப் இயக்குநர்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In லூபஸ் ஆராய்ச்சி கூட்டணி பலகை ஆஃப் இயக்குநர்கள் Today - Breaking & Trending Today

Catalent signs on to produce Aurinia's newly approved lupus nephritis drug

Feb 22, 2021 10:00am
Beyond clinical and commercial manufacturing, Catalent also had a hand in developing the encapsulation process for Aurinia Pharmaceuticals drug Lupkynis. (Catalent)
Just weeks after Aurinia Pharmaceuticals bagged its first FDA green light, the company is turning to one of its clinical manufacturing partners to help bring its drug to market.
Aurinia enlisted Catalent to deliver commercial supply of its oral lupus nephritis drug Lupkynis (voclosporin), the CDMO said Thursday. The multiyear pact follows Lupkynis January green light and the companies successful team-up in the clinic.
Catalent is set to manufacture the drug as a softgel capsule at its site in St. Petersburg, Florida. The 435,000-square-foot facility, chief among the CDMO s North American softgel operations, boasts capacity to turn out 18 billion capsules per year, Catalent said in a release. ....

United States , Switzerland General , Sankt Peterburg , Samsung Biologics , Peter Greenleaf , Aurinia Pharmaceuticals , Lupkyni January , Fierce Pharma , Otsuka Pharmaceutical , Drug Capsules , Drug Manufacturing , Manufacturing Agreement , Commercial Manufacturing , ஒன்றுபட்டது மாநிலங்களில் , சுவிட்சர்லாந்து ஜநரல் , சாம்சங் உயிரியல் , பீட்டர் பச்சை இலை , ஒரினிய மருந்துகள் , கடுமையான பார்மா , ஓத்சுக் மருந்து , மருந்து காப்ஸ்யூல்கள் , மருந்து உற்பத்தி , வணிகரீதியானது உற்பத்தி ,

Companies pan for marketing gold in vaccines

Companies pan for marketing gold in vaccines
For a decade, Jennifer Crow has taken care of her elderly parents, who have multiple sclerosis. After her father had a stroke in December, the family got serious in its conversations with a retirement community and learned that one service it offered was covid-19 vaccination.
They mentioned it like it was an amenity, like We have a swimming pool and a vaccination program, said Crow, a librarian in southern Maryland. It was definitely appealing to me. Vaccines, she felt, would help ease her concerns about whether a congregate living situation would be safe for her parents, and for her to visit them; she has lupus, an autoimmune condition. ....

United States , San Francisco , Alison Taylor , Bob Kocher , Michael Carome , Roberta Clarke , Sarah Ordover , Emily Henderson , Kathryn Stebner , Los Angeles , Patti Patrizi , Tony Chicotel , Boston University , York University , Boston University Clarke , Jennifer Crow , Assisted Living Locators Los Angeles , Senior Living , Vaccine Clinic , California Advocates , Nursing Home Reform , New York , One Medical , Silicon Valley , Corona Virus , Health Care ,

Juvenile inflammatory rheumatic disease associated with higher antibody responses to seasonal coronaviruses

Juvenile inflammatory rheumatic disease associated with higher antibody responses to seasonal coronaviruses
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen behind the current coronavirus disease 2019 (COVID-19) pandemic is a coronavirus of the betacoronavirus family. However, there are other human seasonal coronaviruses that cause endemic human infection, with mild common cold symptoms. The spectrum of SARS-CoV-2 infection also ranges from mild symptoms like a runny nose, nasal congestion or mild fever, to severe gastrointestinal or respiratory disease, sometimes terminating in multi-organ failure.
SARS-CoV-2 vs HCoV-OC43 infection
The complications of COVID-19 are observed in less than a tenth of patients, with risk factors for these including male sex, advanced age, ethnic background, lack of healthcare access, and pre-existing conditions. The majority of infections are asymptomatic. ....

Liji Thomas , Coronavirus Disease Covid 19 , Sars Cov 2 , Common Cold , Corona Virus , Health Care , Juvenile Idiopathic Arthritis , Lupus Erythematosus , Nasal Congestion , Respiratory Disease , Severe Acute Respiratory , Severe Acute Respiratory Syndrome , Systemic Lupus Erythematosus , சர்வதேச பரவல் , வாத நோய் , பொதுவானது குளிர் , கொரோனா வைரஸ் , ஆரோக்கியம் பராமரிப்பு , லூபஸ் எரித்மடோசஸ் , சுவாச நோய் , கடுமையானது எடுப்போசை சுவாச , கடுமையானது எடுப்போசை சுவாச நோய்க்குறி , முறையான லூபஸ் எரித்மடோசஸ் ,

Study reveals role of platelets in the development of lupus

Platelets may play a key role in the development of lupus, according to a study published today by researchers at Université Laval and CHU de Québec-Université Laval Research Center. ....

Paulr Fortin , Emily Henderson , Laval Research Center , Laval Research , Science Translational Medicine , Lead Author , Laval Faculty , Professor Boilard , எமிலி ஹென்டர்சன் , லாவள் ஆராய்ச்சி மையம் , லாவள் ஆராய்ச்சி , அறிவியல் மொழிபெயர்ப்பு மருந்து , வழி நடத்து நூலாசிரியர் , லாவள் ஆசிரிய , ப்ரொஃபெஸர் கொதிகலன் ,

FDA announces drug trial information for new lupus and chronic heart failure medications

FDA announces drug trial information for new lupus and chronic heart failure medications
Food and Drug Administration (generic). (Source: CNN)
By KOLD News 13 Staff | February 10, 2021 at 3:29 PM MST - Updated February 10 at 3:29 PM
TUCSON, Ariz. (KOLD News 13) - Today, the U.S. Food and Drug Adminstration announced the information for two new medications that recently underwent clinical trials.
The first is called
Lupkynis (loop kye’ nis) and is used to treat patients with active lupus [nephritis], an inflammation of the kidneys that is caused by a chronic auto-immune disease.
According to the FDA, patients who received the drug for one year acheived major reduction in kidney inflammation. ....

Drug Adminstration , Side Effects , பக்க விளைவுகள் ,